MiMedx Group, Inc. (NASDAQ:MDXG) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. reduced its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 3.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,705,633 shares of the company's stock after selling 262,667 shares during the quarter. Vanguard Group Inc. owned about 4.56% of MiMedx Group worth $64,508,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in MDXG. Geode Capital Management LLC grew its stake in MiMedx Group by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company's stock worth $16,518,000 after buying an additional 44,254 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in MiMedx Group by 0.7% in the fourth quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company's stock worth $4,849,000 after acquiring an additional 3,300 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of MiMedx Group by 11.8% during the third quarter. Wellington Management Group LLP now owns 317,274 shares of the company's stock worth $1,875,000 after acquiring an additional 33,461 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of MiMedx Group by 133.6% during the third quarter. Jane Street Group LLC now owns 305,652 shares of the company's stock valued at $1,806,000 after acquiring an additional 174,797 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock valued at $1,757,000 after purchasing an additional 215,995 shares during the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

Several analysts have weighed in on the stock. StockNews.com raised shares of MiMedx Group from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 4th. Cantor Fitzgerald reissued an "overweight" rating and set a $13.00 price objective on shares of MiMedx Group in a report on Thursday, February 27th.

Insiders Place Their Bets

In other news, CAO William Frank Iv Hulse sold 54,596 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the transaction, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at $3,473,004.42. The trade was a 11.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 144,018 shares of company stock valued at $1,130,312. Company insiders own 1.30% of the company's stock.

MiMedx Group Stock Performance

NASDAQ MDXG traded down $0.08 during trading hours on Tuesday, reaching $6.69. The stock had a trading volume of 202,633 shares, compared to its average volume of 694,307. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14. The stock has a fifty day moving average of $7.82 and a 200 day moving average of $8.01. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock has a market cap of $985.88 million, a P/E ratio of 12.16 and a beta of 1.74.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. Sell-side analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.